Table 1 Baseline demographics and disease characteristics for the treatment groups assessed (all patients)
TCZ-QW + Pred-26 N = 100 | PBO + Pred-26 N = 50 | PBO + Pred-52 N = 51 | |
|---|---|---|---|
Age, years | 69.5 (8.5) | 69.3 (8.1) | 67.8 (7.7) |
Female, n (%) | 78 (78.0) | 38 (76.0) | 37 (72.5) |
Race, n (%) | |||
White | 97 (97.0) | 50 (100.0) | 49 (96.1) |
Black or African American | 1 (1.0) | 0 | 2 (3.9) |
Asian | 0 | 0 | 0 |
Other | 1 (1.0) | 0 | 0 |
Unknown | 1 (1.0) | 0 | 0 |
Weight, kg | 69.8 (13.8) | 70.1 (15.8) | 73.1 (15.3) |
Disease duration, days | 306.8 (563.5) | 364.7 (569.9) | 255.2 (435.5) |
Disease onset, n (%) | |||
Newly diagnosed | 47 (47.0) | 23 (46.0) | 23 (45.1) |
Relapsing | 53 (53.0) | 27 (54.0) | 28 (54.9) |
Prednisone dose, mg/day | 34.6 (13.4) | 34.6 (13.0) | 34.5 (14.2) |
Cranial signs or symptoms, n (%) | 41 (41.0) | 20 (40.0) | 16 (31.4) |
PMR symptoms | 59 (59.0) | 30 (60.0) | 35 (68.6) |
ESR, mm/h | 24.6 (18.7) | 28.8 (25.4) | 24.2 (18.2) |
SF-36 PCS | 43.1 (9.4) | 42.6 (10.9) | 41.1 (10.0) |
SF-36 MCS | 42.8 (12.4) | 42.7 (12.1) | 40.5 (13.7) |
FACIT-Fatigue | 36.1 (11.1) | 35.0 (12.8) | 31.4 (13.6) |
PtGA, 100 mm VAS | 43.6 (25.7) | 35.7 (28.2) | 47.8 (27.8) |